Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
This article was originally published in The Pink Sheet Daily
Executive Summary
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.